Compare Mesoblast Limited (MESO) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Zeta Global Holdings Corp — how do they compare? Mesoblast Limited trades at $16.31 (market cap $2.11B), while Zeta Global Holdings Corp trades at $20.17 (market cap $5.28B). The key difference: Zeta Global Holdings Corp is far larger — about 2.5× Mesoblast Limited's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | ZETA | |
|---|---|---|
Market Cap | $2.11B | $5.28B |
Sector | Technology | Technology |
52-Week High | $20.96 | $25.24 |
52-Week Low | $12.88 | $14.55 |
Enterprise Value | $2.11B | $5.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
Zeta Global (ZETA) trades at $21.34, down 1.57% on the day, with a neutral technical signal and bullish moving averages. The company reported strong revenue growth, with Q1 2026 EPS beating estimates, but remains unprofitable with a net margin of -1.61%. Recent news highlights a strategic AI partnership with Palantir, positioning Zeta for accelerated growth in marketing technology infrastructure.
The outlook is mixed: analyst consensus is strongly bullish with a $27.50 price target, but profitability concerns and margin pressure pose risks. The stock offers growth potential through AI adoption and partnerships, yet investors must weigh execution risks against transformative opportunities in a competitive sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
